The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
February 2nd 2025
Once-weekly tirzepatide may be an alternative to daily hormone shots in patients with congenital generalized lipodystrophy.
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Targeting Inflammation in Diabetes through Disease-modifying Therapies
July 8th 2014An endocrinologist from the University Hospital Basel in Switzerland discusses the role of inflammation in the pathogenesis of type 2 diabetes, outlining the reasons why clinicians should target inflammation when treating diabetics.
Weight Loss Improves Disease Management in Patients with Psoriatic Arthritis
July 1st 2014Study results show that obese patients with psoriatic arthritis who were treated with tumor necrosis factor-alpha blockers who also lost at least 5 percent of their bodyweight from baseline were much more likely to achieve minimal disease activity.
Does Exercise Actually Increase Your Risk of Atrial Fibrillation?
Data from a large cohort of Swedish men suggest that regular vigorous exercise starting around age 30 may increase the risk of atrial fibrillation, particularly among those who stop exercising later in life.
Transplantation of Human Islet Cells Safe and Effective in Type 1 Diabetes
June 18th 2014Phase III trial shows that transplanted purified human pancreatic islets safely restored sustained near-normoglycemia and provided protection from severe hypoglycemia in patients with long-standing type 1 diabetes and iatrogenic hypoglycemia.
Swedish Study Indicates LDL Cholesterol Not a Good Marker of Cardiovascular Risk in Type 1 Diabetes
June 18th 2014Researchers find that the ratio of total cholesterol to HDL is a significant predictor for CVD in type 1 diabetes patients who are not using lipid-lowering drugs, and that the ratio of total cholesterol to HDL is a more reliable marker for risk when considering primary prevention.